Skip to main content

Posts tagged with "Business and Markets"

  • Business and Markets

    Another STEM Jobs Myth-Breaking Article

    A reader sent along this link to an article at the New York Review of Books on the relentless emphasis on STEM jobs. The viewpoint of its author, Andrew Hacker, was preordained: he’s a political scientist who started a controversy about ten years ago with an editorial wondering if mathematical education (we’re talking up to… Read More
  • Business and Markets

    External R&D

    Bruce Booth has a long post on external R&D in biopharma. He’s mostly talking about some of the newer ways to do that, rather than traditional deals and outsourcing. These include larger companies partnering with VC firms to launch smaller ones, large investments in the smaller players with specific rights to buy some of the… Read More
  • Business and Markets


    I’ve heard from sources this morning that the folks at Bristol-Myers Squibb in Wallingford have received, out of the blue, one of those sudden sitewide meeting announcements that often portend big news. I’ll leave the comments section of this post for updates from anyone with more info – I’ll be out of communication for a… Read More
  • Business and Markets

    Are Things Really Picking Up?

    Is the recent upturn in drug approvals the real thing? Years of overall decline would have to be overcome, but it would be good news if the industry has, in fact, picked back up again. A new article in Nature Reviews Drug Discovery</I. makes the case, based on a measure they're calling the "vintage index". Read More
  • Business and Markets

    The Incomplete Response Letter

    When a drug company’s New Drug Application runs into some sort of major issue, the FDA sends what’s called a CRL, a Complete Response Letter. This details why the application was rejected and what can be done to fix the problem. And all this is, naturally of great interest to the company’s investors. But they… Read More
  • Business and Markets

    Alnylam Sues Dicerna

    Here’s the latest RNAi dustup: Alnylam has filed a “trade secret misappropriation” lawsuit against Dicerna (thanks to a commenter here for mentioning this news). The real issue seems to be use of GalNAc conjugates for delivering siRNAs to the liver. Alnylam’s president, Barry Greene says that “Alnylam has led the disco… Read More
  • Business and Markets

    A Sudden Exit at AstraZeneca

    Hmm. FierceBiotech is reporting that AstraZeneca’s head of R&D, Briggs Morrison, has made a very sudden, very unexpected exit. People seem to have heard about this only this morning, and are being taken by surprise. . . Read More
  • Business and Markets

    Four Patients. Count ‘Em, Four.

    While we’re on the subject of market froth, take a look at what’s going on today. Sage Therapeutics announced the results of a study in post-partum depression. (Note – these are not the same people as Sage Bionetworks out in Seattle; this is a small company in Cambridge). They used SAGE-547, a GABA-A allosteric modulator… Read More
  • Alzheimer's Disease

    More on Axovant’s IPO

    Update: the IPO went off at the top of its range, I am sorry to report. More here from FierceBiotech, and I agree with John Carroll’s take. I wrote just recently about Axovant and their plans to go public with an Alzheimer’s therapy picked up on the cheap from GSK. Now here’s a look from… Read More
  • Business and Markets

    Bristol-Myers Squibb Sues a Former VP

    You don’t often see noncompete agreements invoked in the biopharma industry, but here’s one. According to Pharmalot, Bristol-Myers Squibb is suing a former executive (David Berman) for taking a job with AstraZeneca. Berman was highly placed in BMS’s immuno-oncology area, and this is such a competitive environment that they feel th… Read More